| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EMCN |
| Uniprot No | Q9ULC0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-261aa |
| 氨基酸序列 | MELLQVTILFLLPSICSSNSTGVLEAANNSLVVTTTKPSITTPNTESLQKNVVTPTTGTTPKGTITNELLKMSLMSTATFLTSKDEGLKATTTDVRKNDSIISNVTVTSVTLPNAVSTLQSSKPKTETQSSIKTTEIPGSVLQPDASPSKTGTLTSIPVTIPENTSQSQVIGTEGGKNASTSATSRSYSSIILPVVIALIVITLSVFVLVGLYRMCWKADPGTPENGNDQPQSDKESVKLLTVKTISHESGEHSAQGKTKN |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EMCN(Endomucin)重组蛋白的3篇参考文献示例(内容为模拟，仅供参考)：
1. **文献名称**：*Endomucin重组蛋白抑制血管内皮细胞迁移的机制研究*
**作者**：Zhang Y, et al.
**摘要**：本研究通过体外表达EMCN重组蛋白，发现其能显著抑制VEGF诱导的内皮细胞迁移和血管生成，可能与调控整合素β1信号通路相关，为抗血管治疗提供新靶点。
2. **文献名称**：*重组EMCN蛋白的结构解析及其与VEGFR2的相互作用*
**作者**：Smith J, et al.
**摘要**：通过X射线晶体学解析了EMCN重组蛋白的胞外域结构，发现其通过特定糖基化位点与VEGFR2结合，揭示了其在血管稳态中的潜在调控作用。
3. **文献名称**：*EMCN重组蛋白在小鼠缺血模型中的促血管生成效应*
**作者**：Li H, et al.
**摘要**：实验表明，局部注射EMCN重组蛋白可显著增强小鼠后肢缺血模型的血管新生，并改善血流恢复，提示其作为治疗缺血性疾病的潜在药物。
4. **文献名称**：*Endomucin重组蛋白在肿瘤血管屏障功能中的作用*
**作者**：Wang X, et al.
**摘要**：研究利用EMCN重组蛋白证明其在维持肿瘤血管完整性中的关键作用，敲低EMCN会增加血管渗漏，促进肿瘤细胞外渗，为癌症转移机制提供新见解。
(注：以上文献为示例，实际引用需根据具体研究检索PubMed、Google Scholar等数据库获取真实信息。)
EMCN (Endomucin) is a cell surface glycoprotein predominantly expressed in vascular endothelial cells, playing critical roles in angiogenesis, endothelial cell adhesion, and vascular integrity. As a member of the mucin family, it is characterized by its heavily glycosylated extracellular domain, which contributes to its anti-adhesive properties and interaction with extracellular matrix components. EMCN is encoded by the *EMCN* gene in humans and is evolutionarily conserved, highlighting its functional significance in vascular biology.
Research has shown that EMCN regulates endothelial cell migration and tube formation during angiogenesis by modulating integrin signaling and cytoskeletal dynamics. It also acts as a negative regulator of inflammatory responses in endothelial cells, influencing leukocyte adhesion and vascular permeability. Dysregulation of EMCN expression has been implicated in pathological conditions, including cancer (by promoting tumor angiogenesis), atherosclerosis, and diabetic retinopathy, making it a potential therapeutic target.
Recombinant EMCN protein is produced using expression systems like mammalian or insect cells to ensure proper post-translational modifications, particularly glycosylation, which is essential for its biological activity. This engineered protein serves as a valuable tool for in vitro and in vivo studies to dissect EMCN's molecular mechanisms, screen angiogenesis inhibitors, or develop diagnostic assays. Recent studies also explore its role in tissue engineering, where EMCN-functionalized scaffolds enhance vascularization in regenerative medicine. Ongoing research continues to uncover its interplay with signaling pathways (e.g., VEGF, Notch), further solidifying its relevance in vascular health and disease.
×
